Atara Biotherapeutics falls after FDA puts clinical hold on cancer therapy trials

Atara Biotherapeutics

21/01/2025 13:14

** Shares of drug developer Atara Biotherapeutics  ATRA.O 
fall 4.6% to $6.27 premarket 
    ** Co says the US FDA has placed a clinical hold on trials
testing its experimental cancer cell therapies
    ** The hold applies to studies of co's experimental cancer
therapies, tabelecleucel, and ATA3219 
    ** Co says the hold is related to the issues observed at a
third-party manufacturing facility
     ** The FDA last week declined to approve its cancer therapy
tabelecleucel to treat patients with a rare cancer that develops
after organ or stem cell transplants, due to third-party
manufacturing concerns 
    ** "Atara and FDA have discussed and agreed upon the actions
necessary to release the clinical holds"- ATRA 
    ** Co says it has paused enrollment of new participants in
the trials; adding that some participants "who have the
potential to derive clinical benefit" can continue to receive
treatment 
    ** Up last close, stock had fallen 63.2% in the past 12
months   

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))